QNRX · Insider Trading
Quoin Pharmaceuticals, Ltd. American Depositary Shares
Every open-market purchase and sale reported by QNRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-26 | Dennis Langer | Director | — | — | — |
| 2026-09-01 | Sally Bridget Lawlor | Chief Financial Officer | Buy | +10,244 | +$49.99K |
| 2026-09-01 | Denise P. Carter | Chief Operating Officer | Buy | +20,490 | +$99.99K |
| 2026-09-01 | Anthony James Culverwell | Director | Buy | +6,146 | +$29.99K |
| 2026-09-01 | Michael Myers | Chief Executive Officer | Buy | +20,490 | +$99.99K |
| 2026-08-28 | Anthony James Culverwell | Director | A | +31,352 | +$161.46K |
| 2026-08-28 | Dennis Langer | Director | A | +34,534 | +$177.85K |
| 2026-02-06 | Michael T Sember | Director | A | +8,141 deriv. | — |
| 2026-02-06 | Dennis Langer | Director | A | +21,709 deriv. | — |
| 2026-02-06 | Anthony James Culverwell | Director | A | +21,709 deriv. | — |
| 2026-02-06 | Denise P. Carter | Chief Operating Officer | A | +318,750 deriv. | — |
| 2026-02-06 | Michael Myers | Chief Executive Officer | A | +318,750 deriv. | — |
| 2026-02-06 | Natalie Ee Mun Leong | Director | A | +12,211 deriv. | — |
| 2026-02-06 | Joseph Patrick Cooper | Director | A | +8,141 deriv. | — |
| 2026-02-06 | Sally Bridget Lawlor | Chief Financial Officer | A | +85,250 deriv. | — |
| 2025-12-03 | Sally Bridget Lawlor | Chief Financial Officer | A | +10,330 deriv. | — |
| 2025-10-15 | Dennis Langer | Director | Buy | +15,152 | +$128.64K |
| 2025-08-25 | Anthony James Culverwell | Director | A | +13,682 deriv. | — |
| 2025-08-25 | Dennis Langer | Director | A | +13,682 deriv. | — |
| 2025-08-25 | Natalie Ee Mun Leong | Director | A | +4,105 deriv. | — |
| 2025-06-13 | Denise P. Carter | Chief Operating Officer | A | +42,857 deriv. | — |
| 2025-06-13 | Michael Myers | Chief Executive Officer | A | +42,857 deriv. | — |
| 2025-06-03 | Anthony James Culverwell | Director | A | +7,760 deriv. | — |
| 2025-06-02 | Michael T Sember | Director | A | +7,760 deriv. | — |
| 2025-06-02 | Natalie Ee Mun Leong | Director | A | +7,760 deriv. | — |
| 2025-06-02 | Dennis Langer | Director | A | +7,760 deriv. | — |
| 2025-06-02 | Joseph Patrick Cooper | Director | A | +7,760 deriv. | — |
| 2025-06-02 | Michael Myers | Chief Executive Officer | A | +42,039 deriv. | — |
| 2025-06-02 | Denise P. Carter | Chief Operating Officer | A | +42,039 deriv. | — |
| 2024-12-27 | Gordon Dunn | Chief Financial Officer | Buy | +122,221 | +$55.00K |
| 2024-12-27 | Denise P. Carter | Chief Operating Officer | Buy | +555,556 | +$250.00K |
| 2024-12-27 | Michael Myers | Chief Executive Officer | Buy | +555,556 | +$250.00K |
| 2024-12-27 | Anthony James Culverwell | Director | Buy | +100,000 | +$45.00K |
| 2024-12-10 | Dennis Langer | Director | A | +50,714 deriv. | — |
| 2024-12-10 | Denise P. Carter | Chief Operating Officer | A | +536,609 deriv. | — |
| 2024-12-10 | Anthony James Culverwell | Director | A | +50,714 deriv. | — |
| 2024-12-10 | Michael Myers | Chief Executive Officer | A | +536,603 deriv. | — |
| 2024-12-10 | Gordon Dunn | Chief Financial Officer | A | +338,994 deriv. | — |
| 2024-12-10 | Joseph Patrick Cooper | Director | A | +50,714 deriv. | — |
| 2024-12-10 | Michael T Sember | Director | A | +50,714 deriv. | — |
| 2024-12-10 | Natalie Ee Mun Leong | Director | A | +50,714 deriv. | — |
| 2024-09-11 | Gordon Dunn | Chief Financial Officer | Buy | +28,856 | +$23.20K |
| 2024-09-05 | Denise P. Carter | Chief Operating Officer | Buy | +37,735 | +$28.74K |
| 2024-09-05 | Michael Myers | Chief Executive Officer | Buy | +37,894 | +$28.92K |
| 2024-06-10 | Dennis Langer | Director | Sell | −297 | −$217 |
| 2023-10-30 | Anthony James Culverwell | Director | A | +7,652 deriv. | — |
| 2023-10-30 | Michael Myers | Chief Executive Officer | A | +80,965 deriv. | — |
| 2023-10-30 | Natalie Ee Mun Leong | Director | A | +7,652 deriv. | — |
| 2023-10-30 | Dennis Langer | Director | A | +7,652 deriv. | — |
| 2023-10-30 | Denise P. Carter | Chief Operating Officer | A | +80,966 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Dennis Langer | Director | 49,687 | $194.03K |
| Anthony James Culverwell | Director | 40,364 | $157.62K |
| Michael Myers | Chief Executive Officer | 37,713 | $147.27K |
| Denise P. Carter | Chief Operating Officer | 37,709 | $147.25K |
| Sally Bridget Lawlor | Chief Financial Officer | 10,684 | $41.72K |
| Gordon Dunn | Chief Financial Officer | 4,316 | $16.85K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the QNRX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.